Razvoj novih zaviralcev encimov biosinteze peptidoglikana MurA in MurB (Slovene)
30. April 2017 - 30. April 2019 | 1-09 Natural sciences and Mathematics - Pharmacy
Within the research project, we are pursuing the identification of inhibitors of early steps in peptydoglycan biosynthesis, namely MurA and MurB enzymes. We are employing structure-based design, ligand-based design and fragment based techniques and methodologies and we are performing virtual screening. With the use of organic synthesis, we are preparing focused libr...
Razvoj multifunkcionalnih učinkovin za zdravljenje Alzheimerjeve bolezni (Slovene)
30. April 2017 - 30. April 2020 | 1-09 Natural sciences and Mathematics - Pharmacy
The ageing of the population has resulted in an increase in the number of people with age-related diseases such as dementia. With more than 35 million people affected worldwide, Alzheimer’s disease (AD) is the most prominent form of senile dementia. The number of patients afflicted with this progressive neurodegenerative disorder will continue to grow and is e...
Preprečevanje rezistence tumorskih celic na antiproteazno terapijo z inhibitorji katepsina X (Slovene)
30. April 2017 - 30. April 2020 | 4.06.01 Biotechnical sciences-Biotechnology-Recombinant DNA technology
The progression of malignant diseases is associated with excessive activity of the proteolytic enzymes involved in tumor growth, angiogenesis, migration, invasion and metastasis. Among them is a group of cysteine cathepsins that are present in normal cells in endosomes and lysosomes and are responsible for intracellular protein catabolism. In tumor cells these enzym...
Nanotheranostics based on magneto-responsive materials
31. December 2015 - 30. December 2018 | 1.09 Pharmacy
Various types of cancers represent a great challenge to the health care system nowadays, since 3 million people are diagnosed for cancer annually in Europe. The efficacy of available anticancer medicines and therapeutic approaches is limited and often associated with serious side effects due to unspecific drug distribution in a human body. This problem can be prevented or limited with the incorpor...
Identification of new expression regulators of RANKL, a key molecule not only in bone remodelling
31. December 2015 - 30. December 2018 | 3.07 Metabolic and hormonal disorders
Receptor activator of nuclear factor-κB ligand (RANKL) is a part of the RANKL/RANK/OPG system which plays a crucial role in bone resorption and several other physiological processes. RANKL deregulation has been implicated in osteoporosis (OP), osteoarthritis (OA), autoimmune diseases, chronic inflammatory diseases and various cancers, leading to approval of denosumab, a monoclonal antibody t...
Optimization of nitroxoline-based inhibitors of cathepsin B as potential drugs for the treatment of cancer
31. December 2015 - 30. December 2017 | 1.09 Pharmacy
Human cathepsin B is a lysosomal cysteine protease that has many house-keeping functions, such as intracellular proteolysis. It can act as both an endopeptidase and an exopeptidase, a characteristic that is attributed to a 21-amino-acid insertion above the active site. Dysregulation of cathepsin B activity is associated with many pathological states. The most thorou...